Clinical trials: Nutrition Disorder
Obesity
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of tirzepatide as an addition to healthy lifestyle in participants 6 to less…
- Trial name
- NCT07817875
- Testing
- Tirzepatide
- Where
- 82 sites in United States, Belgium and 8 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Diabetes, Obesity
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in…
- Trial name
- NCT04617275
- Testing
- PF-06882961
- Where
- 38 sites in United States
- Volunteers
- 151 people
- Sponsor
- Pfizer
Obesity
Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on otherwise healthy participants with obesity.
- Trial name
- NCT06970405
- Testing
- Garetosmab
- Sponsor
- Regeneron Pharmaceuticals
Stroke, Ischemic
Investigating Adherence to Cereneo Tele-service Support After Clinical Disharge in Stroke Patients
This observational, prospective cohort, pilot study aims at investigating usability, operational, and economical factors around 'traditional' and 'technology-supported' approaches to promote a healthy life-style in stroke…
- Trial name
- NCT04733339
- Testing
- Secondary Prevention
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Cereneo AG
Obesity
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
The main purpose of this study is to evaluate the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity.
- Trial name
- NCT07812597
- Testing
- zovaglutide Arm 1, zovaglutide Arm 2, semaglutide
- Where
- 16 sites in China
- Volunteers
- 210 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Non-diabetic Overweight or Obese
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects
This is a Phase 1, double-blind, parallel-arm ,placebo-controlled study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), safety and tolerability of BGM0504 following multiple subcutaneous (SC)…
- Trial name
- NCT06714955
- Testing
- Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week., Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Dysphagia, Malnutrition
IDDSI Nutritional Drink for Dysphagia Study
This study will evaluate the gastrointestinal (GI) tolerance, compliance , acceptability and safety of a ready-to-use oral nutritional supplement drink for patients with dysphagia.
- Trial name
- NCT03679078
- Testing
- IDDSI nutritional supplement drink
- Where
- 8 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Nutricia UK Ltd
Obesity
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
This first-in-human study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of ACCG-2671.
- Trial name
- NCT07815678
- Testing
- ACCG-2671
- Where
- 6 sites in United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Obesity
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity.
- Trial name
- NCT06717425
- Testing
- PF-07976016
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Obesity
A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED)
This study will test the hypotheses that a single dose of oxyntomodulin (OXM) will be neutral or better than placebo in lowering ambient glucose levels during a graded glucose infusion (GGI) and that a single dose of OXM will…
- Trial name
- NCT01055340
- Testing
- Oxyntomodulin (OXM), Comparator: Oxyntomodulin (OXM)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
Reinforcement of Surgical Staple Lines Using Peri-Strips Dry (PSD) With Veritas Collagen Matrix
The purpose of this study is to verify the performance of PSD Veritas to provide staple line protection during surgical procedures for obesity.
- Trial name
- RESULTS (NCT00566943)
- Testing
- PSD Veritas Collagen Matrix, Roux-en-Y gastric by-pass surgery with no buttress
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Baxter Healthcare Corporation
Obesity
The USGI Medical ESSENTIAL Study for Weight Loss
This is a multicenter, randomized, evaluator and subject blinded, parallel-group, controlled study intended to evaluate the safety and efficacy of treating obese patients with the placement of g-Cath EZ suture anchors followed by…
- Trial name
- NCT01958385
- Testing
- placement of g-Cath EZ suture anchors, Diet and Exercise
- Where
- 11 sites in United States
- Volunteers
- 377 people
- Sponsor
- USGI Medical
Obesity &Amp; Overweight, Chronic Kidney Disease
UBT251 Injection Phase II Clinical Study (CKD)
This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
- Trial name
- NCT07134335
- Testing
- UBT251
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Overweight, Obese
Acute Effects of Coffee Beverage on Postprandial Inflammation and Oxidative Stress - A Pilot Study
The primary objective is to test if acute supplementation with Coffee would improve antioxidant status, following consumption of a pro-oxidative high carbohydrate, high fat meal in over weight/ obese humans.
- Conditions
- Overweight, Obese, Healthy
- Trial name
- COF1 (NCT02174640)
- Testing
- Coffee, Water
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Obesity & Overweight
A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
The primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.
- Trial name
- NCT07570758
- Testing
- ERX1000
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- ERX Pharmaceuticals
Obesity, Overweight
A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066…
- Trial name
- NCT03100058
- Testing
- LIK066
- Where
- 83 sites in United States, Austria and 5 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Obesity, Overweight
A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity
This study consists of two phases: Phase A and Phase B. Participants are being asked to participate in both phases. Phase A of this study is comparing two formulations of a study medicine called NNC0487-0111 for weight control in…
- Trial name
- NCT06478563
- Testing
- NNC0487-0111 (formulation D), NNC0487-0111 (formulation C)
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- Novo Nordisk A/S
Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
This is a multicenter, randomized, open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 9 mg QW versus Semaglutide 2.4 mg QW in overweight or obese (BMI≥27kg/m2) MAFLD subjects.
- Trial name
- NCT06884293
- Testing
- IBI362, semaglutide
- Where
- China
- Volunteers
- 479 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Morbid Obesity, Weight Loss
Effects of Long Biliopancreatic Limb vs. Long Alimentary Limb in Superobesity, a Randomized Study
Super Obesity, i.e. a BMI above 50, is difficult to treat. Normal gastric bypass surgery is not always enough for proper weight control. Bypassing a longer segment of the gut may be more beneficial.
- Trial name
- NCT01514799
- Testing
- gastric bypass
- Where
- Sweden
- Volunteers
- 140 people
- Sponsor
- Aleris Obesity
Overweight, Obesity
A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of AMG 133 administered alone and in combination with an antiemetic medication, ondansetron, in participants living with overweight or obesity.
- Trial name
- NCT07310563
- Testing
- AMG 133, Ondansetron
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.